{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:11:32Z","timestamp":1790899892082,"version":"4.1.0"},"reference-count":87,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>The prevalence of cardiovascular disease (CVaD) is expected to double in the next 25\u00a0years, fueled by increasing prevalence of diabetes mellitus, obesity and hypertension. Cardiovascular\u2013kidney\u2013metabolic syndrome is a clinical entity requiring a holistic approach to prevention and management. Another aspect of this syndrome is chronic venous disease (CVeD), which is common in patients with CVaD. This review describes presentations at a symposium by the European Association of Preventive Cardiology (Milan, Italy; April 2025), discussing the interconnectedness of conditions on the CVaD continuum and their relationship with CVeD. Venous and arterial disease share common risk factors and pathogenic pathways, including endothelial dysfunction, increased vascular permeability, oxidative stress and inflammation. Many cardiometabolic and vascular conditions remain underdiagnosed and untreated, and the patients\u2019 level of risk is often underestimated. Examination of the legs is important to identify peripheral arterial disease and\/or CVeD. The mainstays of treatment for CVeD are exercise, compression therapy, venoactive drugs and surgery. Failure to achieve and maintain treatment goals is usually the result of therapeutic inertia or poor medication adherence. A coherent approach is needed to identify and manage shared risk factors and comorbidities. Effective disease management and risk reduction require integrated care using multidisciplinary teams; evidence-based treatments, usually with combination therapy; and use of tools to maximize adherence, including digital tools and single-pill combinations to simplify treatment regimens in patients with multiple risk factors or comorbidities.<\/jats:p>","DOI":"10.57264\/cer-2025-0162","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:52:14Z","timestamp":1769161934000},"source":"Crossref","is-referenced-by-count":1,"title":["Reshaping the cardiovascular continuum in the management of arterial and venous cardiovascular disease: a narrative review"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3632-4336","authenticated-orcid":false,"given":"Khadija","family":"Hafidh","sequence":"first","affiliation":[{"name":"Dubai Academic Health Corporation, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina Vega","family":"de Ceniga","sequence":"additional","affiliation":[{"name":"University Hospital of Galdakao-Usansolo, Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo De","family":"Luca","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"name":"University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"11","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","volume":"32","author":"Chong B","year":"2025","unstructured":"Chong B, Jayabaskaran J, Jauhari SM Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur. J. Prev. Cardiol. 32(11), 1001\u20131015 (2025).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"e_1_3_8_4_2","first-page":"7","article-title":"A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention","volume":"15","author":"Chrysant SG","year":"2011","unstructured":"Chrysant SG. A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention. Hippokratia 15(1), 7\u201311 (2011).","journal-title":"Hippokratia"},{"issue":"25","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan M","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV The global burden of cardiovascular diseases and risk: a compass for future health. J. Am. Coll. Cardiol. 80(25), 2361\u20132371 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.ajpc.2021.100149","article-title":"Ten things to know about ten cardiovascular disease risk factors","volume":"5","author":"Bays HE","year":"2021","unstructured":"Bays HE, Taub PR, Epstein E Ten things to know about ten cardiovascular disease risk factors. Am. J. Prev. Cardiol. 5, 100149 (2021).","journal-title":"Am. J. Prev. Cardiol."},{"issue":"20","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele CE","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148(20), 1636\u20131664 (2023).","journal-title":"Circulation"},{"key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"118528","DOI":"10.1016\/j.atherosclerosis.2024.118528","article-title":"Rising to the challenge of cardio-renal-metabolic disease in the 21st century: translating evidence into best clinical practice to prevent and manage atherosclerosis","volume":"396","author":"International Cardiometabolic Working Group","year":"2024","unstructured":"International Cardiometabolic Working Group, Krentz A, Jacob S Rising to the challenge of cardio-renal-metabolic disease in the 21st century: translating evidence into best clinical practice to prevent and manage atherosclerosis. Atherosclerosis 396, 118528 (2024).","journal-title":"Atherosclerosis"},{"issue":"40","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1093\/eurheartj\/ehab589","article-title":"The legs are a pathway to the heart: connections between chronic venous insufficiency and cardiovascular disease","volume":"42","author":"Hamburg NM","year":"2021","unstructured":"Hamburg NM. The legs are a pathway to the heart: connections between chronic venous insufficiency and cardiovascular disease. Eur. Heart J. 42(40), 4166\u20134168 (2021).","journal-title":"Eur. Heart J."},{"issue":"9","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1161\/CIR.0000000000000652","article-title":"Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association","volume":"139","author":"McClellan M","year":"2019","unstructured":"McClellan M, Brown N, Califf RM Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation 139(9), e44\u2013e54 (2019).","journal-title":"Circulation"},{"issue":"1","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","article-title":"European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication","volume":"67","author":"Nordanstig J","year":"2024","unstructured":"Nordanstig J, Behrendt CA, Baumgartner I European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur. J. Vasc. Endovasc. Surg. 67(1), 9\u201396 (2024).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"3","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ehjqcco\/qcw057","article-title":"Long-term survival and fate of the leg in de novo intermittent claudication","volume":"3","author":"Kumakura H","year":"2017","unstructured":"Kumakura H, Kanai H, Hojo Y Long-term survival and fate of the leg in de novo intermittent claudication. Eur. Heart J. Qual. Care Clin. Outcomes 3(3), 208\u2013215 (2017).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"issue":"2","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejvs.2020.11.013","article-title":"Editor's Choice - The GermanVasc Score: a pragmatic risk score predicts five year amputation free survival in patients with peripheral arterial occlusive disease","volume":"61","author":"Kreutzburg T","year":"2021","unstructured":"Kreutzburg T, Peters F, Kuchenbecker J Editor's Choice - The GermanVasc Score: a pragmatic risk score predicts five year amputation free survival in patients with peripheral arterial occlusive disease. Eur. J. Vasc. Endovasc. Surg. 61(2), 248\u2013256 (2021).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"4","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejvs.2018.01.019","article-title":"Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome","volume":"55","author":"Sartipy F","year":"2018","unstructured":"Sartipy F, Sigvant B, Lundin F Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome. Eur. J. Vasc. Endovasc. Surg. 55(4), 529\u2013536 (2018).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"6","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jvs.2004.09.027","article-title":"Revision of the CEAP classification for chronic venous disorders: consensus statement","volume":"40","author":"Ekl\u00f6f B","year":"2004","unstructured":"Ekl\u00f6f B, Rutherford RB, Bergan JJ Revision of the CEAP classification for chronic venous disorders: consensus statement. J. Vasc. Surg. 40(6), 1248\u20131252 (2004).","journal-title":"J. Vasc. Surg."},{"issue":"9","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0003319718759834","article-title":"An epidemiological survey of venous disease among general practitioner attendees in different geographical regions on the globe: the final results of the Vein Consult Program","volume":"69","author":"Vuylsteke ME","year":"2018","unstructured":"Vuylsteke ME, Colman R, Thomis S An epidemiological survey of venous disease among general practitioner attendees in different geographical regions on the globe: the final results of the Vein Consult Program. Angiology 69(9), 779\u2013785 (2018).","journal-title":"Angiology"},{"issue":"1","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0037-1622252","article-title":"Propsective epidemiological study on the beginning of varicose veins","volume":"38","author":"Schultz-Ehrenburg U","year":"2009","unstructured":"Schultz-Ehrenburg U, Reich-Schupke S, Robak-Pawelczyk B Propsective epidemiological study on the beginning of varicose veins. Phlebologie 38(1), 17\u201325 (2009).","journal-title":"Phlebologie"},{"issue":"1","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jvsv.2014.09.008","article-title":"Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study","volume":"3","author":"Lee AJ","year":"2015","unstructured":"Lee AJ, Robertson LA, Boghossian SM Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J. Vasc. Surg. Venous Lymphat. Disord. 3(1), 18\u201326 (2015).","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"issue":"6","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/SLA.0000000000004631","article-title":"Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis","volume":"274","author":"Salim S","year":"2021","unstructured":"Salim S, Machin M, Patterson BO Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann. Surg. 274(6), 971\u2013976 (2021).","journal-title":"Ann. Surg."},{"issue":"40","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1093\/eurheartj\/ehab495","article-title":"Chronic venous insufficiency, cardiovascular disease, and mortality: a population study","volume":"42","author":"Prochaska JH","year":"2021","unstructured":"Prochaska JH, Arnold N, Falcke A Chronic venous insufficiency, cardiovascular disease, and mortality: a population study. Eur. Heart J. 42(40), 4157\u20134165 (2021).","journal-title":"Eur. Heart J."},{"issue":"3","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jvsv.2021.08.021","article-title":"Association of chronic venous disease with major adverse cardiovascular events","volume":"10","author":"Singh TP","year":"2022","unstructured":"Singh TP, Velu RB, Quigley F Association of chronic venous disease with major adverse cardiovascular events. J. Vasc. Surg. Venous Lymphat. Disord. 10(3), 683\u2013688 (2022).","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"issue":"6","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"e034245","DOI":"10.1136\/bmjopen-2019-034245","article-title":"Severe varicose veins and the risk of mortality: a nationwide population-based cohort study","volume":"10","author":"Wu NC","year":"2020","unstructured":"Wu NC, Chen ZC, Feng IJ Severe varicose veins and the risk of mortality: a nationwide population-based cohort study. BMJ Open 10(6), e034245 (2020).","journal-title":"BMJ Open"},{"issue":"10","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.31083\/j.rcm2510357","article-title":"Causal association of chronic venous insufficiency and cardiovascular diseases: a univariable and multivariable mendelian randomization study","volume":"25","author":"Guo X","year":"2024","unstructured":"Guo X, Zhang K, Sun Y Causal association of chronic venous insufficiency and cardiovascular diseases: a univariable and multivariable mendelian randomization study. Rev. Cardiovasc. Med. 25(10), 357 (2024).","journal-title":"Rev. Cardiovasc. Med."},{"issue":"1","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi M","year":"2023","unstructured":"Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc. Diabetol. 22(1), 195 (2023).","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"e_1_3_8_25_2","first-page":"575","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie JR","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can. J. Cardiol. 34(5), 575\u2013584 (2018).","journal-title":"Can. J. Cardiol."},{"issue":"2","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0003319712439092","article-title":"Peripheral arterial disease is prevalent but underdiagnosed and undertreated in the primary care setting in central Greece","volume":"64","author":"Argyriou C","year":"2013","unstructured":"Argyriou C, Saleptsis V, Koutsias S Peripheral arterial disease is prevalent but underdiagnosed and undertreated in the primary care setting in central Greece. Angiology 64(2), 119\u2013124 (2013).","journal-title":"Angiology"},{"issue":"9","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1742-1241.2007.01423.x","article-title":"Under-diagnosis of common chronic diseases: prevalence and impact on human health","volume":"61","author":"Falagas ME","year":"2007","unstructured":"Falagas ME, Vardakas KZ, Vergidis PI. Under-diagnosis of common chronic diseases: prevalence and impact on human health. Int. J. Clin. Pract. 61(9), 1569\u20131579 (2007).","journal-title":"Int. J. Clin. Pract."},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0158"},{"issue":"1","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.numecd.2023.09.023","article-title":"LDL-cholesterol target levels achievement in high-risk patients: an (un)expected gender bias","volume":"34","author":"Berteotti M","year":"2024","unstructured":"Berteotti M, Profili F, Nreu B LDL-cholesterol target levels achievement in high-risk patients: an (un)expected gender bias. Nutr. Metab. Cardiovasc. Dis. 34(1), 145\u2013152 (2024).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"5","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s12325-020-01285-2","article-title":"Proportion of high-risk\/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to european guidelines: a systematic review","volume":"37","author":"Bruckert E","year":"2020","unstructured":"Bruckert E, Parhofer KG, Gonzalez-Juanatey JR Proportion of high-risk\/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to european guidelines: a systematic review. Adv. Ther. 37(5), 1724\u20131736 (2020).","journal-title":"Adv. Ther."},{"key":"e_1_3_8_31_2","first-page":"200364","article-title":"Goal attainment, medication adherence and guideline adherence in the treatment of hypertension and dyslipidemia in Irish populations: a systematic review and meta-analysis","volume":"24","author":"Elhiny R","year":"2025","unstructured":"Elhiny R, O'Keeffe LM, Bodunde EO Goal attainment, medication adherence and guideline adherence in the treatment of hypertension and dyslipidemia in Irish populations: a systematic review and meta-analysis. Int. J. Cardiol. Cardiovasc. Risk Prev. 24, 200364 (2025).","journal-title":"Int. J. Cardiol. Cardiovasc. Risk Prev."},{"issue":"3","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4093\/dmj.2021.0088","article-title":"Current status of low-density lipoprotein cholesterol target achievement in patients with Type 2 diabetes mellitus in Korea compared with recent guidelines","volume":"46","author":"Yun SJ","year":"2021","unstructured":"Yun SJ, Jeong IK, Cha JH Current status of low-density lipoprotein cholesterol target achievement in patients with Type 2 diabetes mellitus in Korea compared with recent guidelines. Diabetes Metab. J. 46(3), 464\u2013475 (2021).","journal-title":"Diabetes Metab. J."},{"issue":"4","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/1074248419899298","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) goal achievement in high-cardiovascular-risk patients in Fuzhou, China","volume":"25","author":"Wang X","year":"2020","unstructured":"Wang X, He Y, Wang T Lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) goal achievement in high-cardiovascular-risk patients in Fuzhou, China. J. Cardiovasc. Pharmacol. Ther. 25(4), 307\u2013315 (2020).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"2","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jash.2013.07.009","article-title":"Review of blood pressure control rates and outcomes","volume":"8","author":"Bakris G","year":"2014","unstructured":"Bakris G, Sarafidis P, Agarwal R Review of blood pressure control rates and outcomes. J. Am. Soc. Hypertens. 8(2), 127\u2013141 (2014).","journal-title":"J. Am. Soc. Hypertens."},{"issue":"3","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/HYPERTENSIONAHA.124.24013","article-title":"Time in target range for blood pressure and adverse health outcomes: a systematic review","volume":"82","author":"Wang H","year":"2025","unstructured":"Wang H, Song J, Liu Z Time in target range for blood pressure and adverse health outcomes: a systematic review. Hypertension 82(3), 419\u2013431 (2025).","journal-title":"Hypertension"},{"issue":"6","key":"e_1_3_8_36_2","first-page":"e26180","article-title":"Glycemic control for Type 2 diabetes mellitus patients: a systematic review","volume":"14","author":"Bin Rakhis SA","year":"2022","unstructured":"Bin Rakhis SA Sr, AlDuwayhis NM, Aleid N Glycemic control for Type 2 diabetes mellitus patients: a systematic review. Cureus 14(6), e26180 (2022).","journal-title":"Cureus"},{"key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"469580231155716","DOI":"10.1177\/00469580231155716","article-title":"Prevalence of glycemic control and factors associated with poor glycemic control: a systematic review and meta-analysis","volume":"60","author":"Bitew ZW","year":"2023","unstructured":"Bitew ZW, Alemu A, Jember DA Prevalence of glycemic control and factors associated with poor glycemic control: a systematic review and meta-analysis. Inquiry 60, 469580231155716 (2023).","journal-title":"Inquiry"},{"issue":"1","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"18936","DOI":"10.1038\/s41598-022-21916-8","article-title":"Medication non-adherence and therapeutic inertia independently contribute to poor disease control for cardiometabolic diseases","volume":"12","author":"Yan X","year":"2022","unstructured":"Yan X, Mudiganti S, Husby H Medication non-adherence and therapeutic inertia independently contribute to poor disease control for cardiometabolic diseases. Sci. Rep. 12(1), 18936 (2022).","journal-title":"Sci. Rep."},{"key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon R","year":"2011","unstructured":"Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343, d4169 (2011).","journal-title":"BMJ"},{"issue":"1","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis","volume":"178","author":"Brunstr\u00f6m M","year":"2018","unstructured":"Brunstr\u00f6m M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern. Med. 178(1), 28\u201336 (2018).","journal-title":"JAMA Intern. Med."},{"issue":"9539","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study","volume":"368","author":"Deedwania P","year":"2006","unstructured":"Deedwania P, Barter P, Carmena R Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368(9539), 919\u2013928 (2006).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/080370502753543945","article-title":"Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe","volume":"11","author":"Hansson L","year":"2002","unstructured":"Hansson L, Lloyd A, Anderson P Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 11(1), 35\u201345 (2002).","journal-title":"Blood Press."},{"issue":"1","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/jcm9010246","article-title":"Association between on-treatment haemoglobin A1c and all-cause mortality in individuals with Type 2 diabetes: importance of personalized goals and type of anti-hyperglycaemic treatment","volume":"9","author":"Orsi E","year":"2020","unstructured":"Orsi E, Bonora E, Solini A Association between on-treatment haemoglobin A1c and all-cause mortality in individuals with Type 2 diabetes: importance of personalized goals and type of anti-hyperglycaemic treatment. J. Clin. Med. 9(1), 246 (2020).","journal-title":"J. Clin. Med."},{"issue":"1","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"9922","DOI":"10.1038\/s41467-024-54078-4","article-title":"Effectiveness of treat-to-target cholesterol-lowering interventions on cardiovascular disease and all-cause mortality risk in the community-dwelling population: a target trial emulation","volume":"15","author":"Yang Z","year":"2024","unstructured":"Yang Z, Deng Q, Hao Y Effectiveness of treat-to-target cholesterol-lowering interventions on cardiovascular disease and all-cause mortality risk in the community-dwelling population: a target trial emulation. Nat. Commun. 15(1), 9922 (2024).","journal-title":"Nat. Commun."},{"issue":"5","key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc15-2439","article-title":"Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study","volume":"39","author":"Wong ND","year":"2016","unstructured":"Wong ND, Zhao Y, Patel R Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. Diabetes Care 39(5), 668\u2013676 (2016).","journal-title":"Diabetes Care"},{"issue":"5","key":"e_1_3_8_46_2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.amjcard.2011.04.016","article-title":"Effect of cholesterol on mortality and quality of life up to a 46-year follow-up","volume":"108","author":"Hyttinen L","year":"2011","unstructured":"Hyttinen L, Strandberg TE, Strandberg AY Effect of cholesterol on mortality and quality of life up to a 46-year follow-up. Am. J. Cardiol. 108(5), 677\u2013681 (2011).","journal-title":"Am. J. Cardiol."},{"issue":"17","key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/jama.280.17.1490","article-title":"Health economic benefits and quality of life during improved glycemic control in patients with Type 2 diabetes mellitus: a randomized, controlled, double-blind trial","volume":"280","author":"Testa MA","year":"1998","unstructured":"Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with Type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 280(17), 1490\u20131496 (1998).","journal-title":"JAMA"},{"issue":"12","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1007\/s12325-023-02657-0","article-title":"Cardiovascular insights for the appropriate management of chronic venous disease: a narrative review of implications for the use of venoactive drugs","volume":"40","author":"Gianesini S","year":"2023","unstructured":"Gianesini S, De Luca L, Feodor T Cardiovascular insights for the appropriate management of chronic venous disease: a narrative review of implications for the use of venoactive drugs. Adv. Ther. 40(12), 5137\u20135154 (2023).","journal-title":"Adv. Ther."},{"key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2023.04.013","article-title":"Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain","volume":"375","author":"Cos\u00edn-Sales J","year":"2023","unstructured":"Cos\u00edn-Sales J, Campuzano Ruiz R, D\u00edaz D\u00edaz JL Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain. Atherosclerosis 375, 38\u201344 (2023).","journal-title":"Atherosclerosis"},{"key":"e_1_3_8_50_2","doi-asserted-by":"crossref","first-page":"1295174","DOI":"10.3389\/fcvm.2023.1295174","article-title":"Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study","volume":"10","author":"Prieto-D\u00edaz MA","year":"2023","unstructured":"Prieto-D\u00edaz MA, Pallares-Carratala V, Manuel Mic\u00f3-P\u00e9rez R Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study. Front. Cardiovasc. Med. 10, 1295174 (2023).","journal-title":"Front. Cardiovasc. Med."},{"issue":"6","key":"e_1_3_8_51_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2459\/JCM.0000000000001734","article-title":"Multidisciplinary approach and combination pharmacotherapy for the management of cardiometabolic patients","volume":"26","author":"Rosano GMC","year":"2025","unstructured":"Rosano GMC, Vitale C, Spoletini I Multidisciplinary approach and combination pharmacotherapy for the management of cardiometabolic patients. J. Cardiovasc. Med. (Hagerstown) 26(6), 297\u2013302 (2025).","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"issue":"4","key":"e_1_3_8_52_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc14-2098","article-title":"Determinants of adherence to diabetes medications: findings from a large pharmacy claims database","volume":"38","author":"Kirkman MS","year":"2015","unstructured":"Kirkman MS, Rowan-Martin MT, Levin R Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care 38(4), 604\u2013609 (2015).","journal-title":"Diabetes Care"},{"issue":"2","key":"e_1_3_8_53_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejvs.2021.12.024","article-title":"Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs","volume":"63","author":"De Maeseneer MG","year":"2022","unstructured":"De Maeseneer MG, Kakkos SK, Aherne T Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur. J. Vasc. Endovasc. Surg. 63(2), 184\u2013267 (2022).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"3","key":"e_1_3_8_54_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.23736\/S0392-9590.18.03999-8","article-title":"Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I","volume":"37","author":"Nicolaides A","year":"2018","unstructured":"Nicolaides A, Kakkos S, Baekgaard N Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int. Angiol. 37(3), 181\u2013254 (2018).","journal-title":"Int. Angiol."},{"issue":"3","key":"e_1_3_8_55_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.23736\/S0392-9590.20.04388-6","article-title":"Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part II","volume":"39","author":"Nicolaides A","year":"2020","unstructured":"Nicolaides A, Kakkos S, Baekgaard N Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part II. Int. Angiol. 39(3), 175\u2013240 (2020).","journal-title":"Int. Angiol."},{"key":"e_1_3_8_56_2","doi-asserted-by":"crossref","first-page":"133290","DOI":"10.1016\/j.ijcard.2025.133290","article-title":"LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry","volume":"433","author":"Colivicchi F","year":"2025","unstructured":"Colivicchi F, Fabbri G, Oliva F LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry. Int. J. Cardiol. 433, 133290 (2025).","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"e_1_3_8_57_2","doi-asserted-by":"crossref","first-page":"ehae666.2549","DOI":"10.1093\/eurheartj\/ehae666.2549","article-title":"Blood pressure control and cardiovascular risk assessment in patients with hypertension: a pooled analysis of 6 countries in Eastern and Southern Europ (SNAPSHOT study)","volume":"45","author":"Camafort M","year":"2024","unstructured":"Camafort M, Dzudie A, Ivanovic B Blood pressure control and cardiovascular risk assessment in patients with hypertension: a pooled analysis of 6 countries in Eastern and Southern Europ (SNAPSHOT study). Eur. Heart J. 45(Suppl. 1), ehae666.2549 (2024).","journal-title":"Eur. Heart J."},{"issue":"3","key":"e_1_3_8_58_2","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1097\/01.hjh.0001063400.44743.15","article-title":"Cardiovascular risk assessment in hypertensive patients with Type 2 diabetes: a cross-sectional epidemiological study in Colombia (SNAPSHOT study)","volume":"42","author":"Quintero-Baiz A","year":"2024","unstructured":"Quintero-Baiz A, Benavides JAC, Correa RCR Cardiovascular risk assessment in hypertensive patients with Type 2 diabetes: a cross-sectional epidemiological study in Colombia (SNAPSHOT study). J. Hypertens. 42(Suppl. 3), e106 (2024).","journal-title":"J. Hypertens."},{"issue":"3","key":"e_1_3_8_59_2","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/01.hjh.0001063324.09253.d0","article-title":"Cardiovascular risk factor control in hypertensive patients with Type 2 diabetes: a cross-sectional epidemiological study in Colombia (SNAPSHOT study)","volume":"42","author":"Quintero-Baiz A","year":"2024","unstructured":"Quintero-Baiz A, Herazo JJB, Gomez JOI Cardiovascular risk factor control in hypertensive patients with Type 2 diabetes: a cross-sectional epidemiological study in Colombia (SNAPSHOT study). J. Hypertens. 42(Suppl. 3), e98\u2013e99 (2024).","journal-title":"J. Hypertens."},{"issue":"25","key":"e_1_3_8_60_2","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group, ESC Cardiovascular risk collaboration","year":"2021","unstructured":"SCORE2 working group, ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J. 42(25), 2439\u20132454 (2021).","journal-title":"Eur. Heart J."},{"issue":"25","key":"e_1_3_8_61_2","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2-OP working group, ESC Cardiovascular risk collaboration","year":"2021","unstructured":"SCORE2-OP working group, ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur. Heart J. 42(25), 2455\u20132467 (2021).","journal-title":"Eur. Heart J."},{"issue":"5","key":"e_1_3_8_62_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/2047487312449590","article-title":"Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey","volume":"20","author":"Erdine S","year":"2013","unstructured":"Erdine S, Redon J, Bohm M Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. Eur. J. Prev. Cardiol. 20(5), 786\u2013792 (2013).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"9","key":"e_1_3_8_63_2","doi-asserted-by":"crossref","first-page":"e24569","DOI":"10.1371\/journal.pone.0024569","article-title":"Physician perception of blood pressure control and treatment behavior in high-risk hypertensive patients: a cross-sectional study","volume":"6","author":"Banegas JR","year":"2011","unstructured":"Banegas JR, Lundelin K, de la Figuera M Physician perception of blood pressure control and treatment behavior in high-risk hypertensive patients: a cross-sectional study. PLOS One 6(9), e24569 (2011).","journal-title":"PLOS One"},{"issue":"3","key":"e_1_3_8_64_2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s12325-024-03103-5","article-title":"Improving therapeutic adherence and reducing therapeutic inertia in the management of people with cardiometabolic diseases: a call-to-action from the middle east","volume":"42","author":"Almahmeed W","year":"2025","unstructured":"Almahmeed W, Alabadla Z, Al Awadi F Improving therapeutic adherence and reducing therapeutic inertia in the management of people with cardiometabolic diseases: a call-to-action from the middle east. Adv. Ther. 42(3), 1340\u20131359 (2025).","journal-title":"Adv. Ther."},{"issue":"4","key":"e_1_3_8_65_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2337\/cd20-0053","article-title":"Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association","volume":"38","author":"Gabbay RA","year":"2020","unstructured":"Gabbay RA, Kendall D, Beebe C Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association. Clin. Diabetes 38(4), 371\u2013381 (2020).","journal-title":"Clin. Diabetes"},{"issue":"13","key":"e_1_3_8_66_2","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention: time to move the bar","volume":"74","author":"Dixon DL","year":"2019","unstructured":"Dixon DL, Sharma G, Sandesara PB Therapeutic inertia in cardiovascular disease prevention: time to move the bar. J. Am. Coll. Cardiol. 74(13), 1728\u20131731 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"e_1_3_8_67_2","doi-asserted-by":"crossref","first-page":"100160","DOI":"10.1016\/j.jacadv.2022.100160","article-title":"The multidisciplinary heart team in cardiovascular medicine: current role and future challenges","volume":"2","author":"Batchelor WB","year":"2023","unstructured":"Batchelor WB, Anwaruddin S, Wang DD The multidisciplinary heart team in cardiovascular medicine: current role and future challenges. JACC Adv. 2(1), 100160 (2023).","journal-title":"JACC Adv."},{"issue":"12","key":"e_1_3_8_68_2","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia G","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens. 41(12), 1874\u20132071 (2023).","journal-title":"J. Hypertens."},{"issue":"38","key":"e_1_3_8_69_2","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy JW","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 45(38), 3912\u20134018 (2024).","journal-title":"Eur. Heart J."},{"issue":"36","key":"e_1_3_8_70_2","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints C","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur. Heart J. 45(36), 3415\u20133537 (2024).","journal-title":"Eur. Heart J."},{"issue":"24","key":"e_1_3_8_71_2","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","article-title":"Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand","volume":"22","author":"Szwed H","year":"2001","unstructured":"Szwed H, Sadowski Z, Elikowski W Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart J. 22(24), 2267\u20132274 (2001).","journal-title":"Eur. Heart J."},{"issue":"1","key":"e_1_3_8_72_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00044011-199713010-00002","article-title":"Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina","volume":"13","author":"Michaelides AP","year":"1997","unstructured":"Michaelides AP, Spiropoulos K, Dimopoulos K Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Investig. 13(1), 8\u201314 (1997).","journal-title":"Clin Drug Investig."},{"issue":"9","key":"e_1_3_8_73_2","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve S","year":"2009","unstructured":"Karve S, Cleves MA, Helm M Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr. Med. Res. Opin. 25(9), 2303\u20132310 (2009).","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"e_1_3_8_74_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/10600280241262513","article-title":"Medication adherence and treatment satisfaction with lipid-lowering drugs among patients with diabetes and dyslipidemia","volume":"59","author":"Alfadda AA","year":"2025","unstructured":"Alfadda AA, Youssef AM, Al-Sofiani ME Medication adherence and treatment satisfaction with lipid-lowering drugs among patients with diabetes and dyslipidemia. Ann. Pharmacother. 59(2), 105\u2013116 (2025).","journal-title":"Ann. Pharmacother."},{"issue":"12","key":"e_1_3_8_75_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/pds.1671","article-title":"Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients","volume":"17","author":"Choudhry NK","year":"2008","unstructured":"Choudhry NK, Setoguchi S, Levin R Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol. Drug Saf. 17(12), 1189\u20131196 (2008).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"13","key":"e_1_3_8_76_2","doi-asserted-by":"crossref","first-page":"e030264","DOI":"10.1161\/JAHA.122.030264","article-title":"Persistence and adherence to cardiovascular medicines in Australia","volume":"12","author":"de Oliveira Costa J","year":"2023","unstructured":"de Oliveira Costa J, Lin J, Pearson SA Persistence and adherence to cardiovascular medicines in Australia. J. Am. Heart Assoc. 12(13), e030264 (2023).","journal-title":"J. Am. Heart Assoc."},{"issue":"10","key":"e_1_3_8_77_2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","article-title":"Predictors of adherence with antihypertensive and lipid-lowering therapy","volume":"165","author":"Chapman RH","year":"2005","unstructured":"Chapman RH, Benner JS, Petrilla AA Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 165(10), 1147\u20131152 (2005).","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"e_1_3_8_78_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41569-023-00972-1","article-title":"Improving medication adherence in cardiovascular disease","volume":"21","author":"Nelson AJ","year":"2024","unstructured":"Nelson AJ, Pagidipati NJ, Bosworth HB. Improving medication adherence in cardiovascular disease. Nat. Rev. Cardiol. 21(6), 417\u2013429 (2024).","journal-title":"Nat. Rev. Cardiol."},{"issue":"16","key":"e_1_3_8_79_2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2146\/ajhp080238","article-title":"Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy","volume":"66","author":"Benner JS","year":"2009","unstructured":"Benner JS, Chapman RH, Petrilla AA Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am. J. Health Syst. Pharm. 66(16), 1471\u20131477 (2009).","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1","key":"e_1_3_8_80_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/HJH.0000000000003570","article-title":"A real-world analysis of outcomes and healthcare costs of patients on perindopril\/indapamide\/amlodipine single-pill vs. multiple-pill combination in Italy","volume":"42","author":"Snyman JR","year":"2024","unstructured":"Snyman JR, Bortolotto LA, Degli Esposti L A real-world analysis of outcomes and healthcare costs of patients on perindopril\/indapamide\/amlodipine single-pill vs. multiple-pill combination in Italy. J. Hypertens. 42(1), 136\u2013142 (2024).","journal-title":"J. Hypertens."},{"issue":"8","key":"e_1_3_8_81_2","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1007\/s12325-024-02916-8","article-title":"Differential adherence to free and single-pill combination of rosuvastatin\/ezetimibe: findings from a real-world analysis in Italy","volume":"41","author":"Perez de Isla L","year":"2024","unstructured":"Perez de Isla L, Liberopoulos E, Dovizio M Differential adherence to free and single-pill combination of rosuvastatin\/ezetimibe: findings from a real-world analysis in Italy. Adv. Ther. 41(8), 3407\u20133418 (2024).","journal-title":"Adv. Ther."},{"issue":"5","key":"e_1_3_8_82_2","doi-asserted-by":"crossref","first-page":"oeae074","DOI":"10.1093\/ehjopen\/oeae074","article-title":"A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin\/ezetimibe as single-pill combination vs. free combination in Italy","volume":"4","author":"Zambon A","year":"2024","unstructured":"Zambon A, Liberopoulos E, Dovizio M A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin\/ezetimibe as single-pill combination vs. free combination in Italy. Eur. Heart J. Open 4(5), oeae074 (2024).","journal-title":"Eur. Heart J. Open"},{"key":"e_1_3_8_83_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.curtheres.2017.01.005","article-title":"Safety, efficacy, and bioavailability of fixed-dose combinations in Type 2 diabetes mellitus: a systematic updated review","volume":"84","author":"Vijayakumar TM","year":"2017","unstructured":"Vijayakumar TM, Jayram J, Meghana Cheekireddy V Safety, efficacy, and bioavailability of fixed-dose combinations in Type 2 diabetes mellitus: a systematic updated review. Curr. Ther. Res. Clin. Exp. 84, 4\u20139 (2017).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"1","key":"e_1_3_8_84_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12933-025-02936-w","article-title":"Fixed-dose vs loose-dose combination antidiabetic therapy and cardiorenal outcomes in Type 2 diabetes: a nationwide comparative effectiveness study","volume":"24","author":"Liu Q","year":"2025","unstructured":"Liu Q, Welsh P, Celis-Morales C Fixed-dose vs loose-dose combination antidiabetic therapy and cardiorenal outcomes in Type 2 diabetes: a nationwide comparative effectiveness study. Cardiovasc. Diabetol. 24(1), 365 (2025).","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"e_1_3_8_85_2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1186\/s12889-025-21818-0","article-title":"Text messages as a tool to improve cardiovascular disease risk factors control: a systematic review and meta-analysis of randomized clinical trials","volume":"25","author":"Calderon Martinez E","year":"2025","unstructured":"Calderon Martinez E, Zachariah Saji S, Salazar Ore JV Text messages as a tool to improve cardiovascular disease risk factors control: a systematic review and meta-analysis of randomized clinical trials. BMC Public Health 25(1), 1284 (2025).","journal-title":"BMC Public Health"},{"issue":"4","key":"e_1_3_8_86_2","first-page":"CD012925","article-title":"Digital tracking, provider decision support systems, and targeted client communication via mobile devices to improve primary health care","volume":"4","author":"Agarwal S","year":"2025","unstructured":"Agarwal S, Chin WY, Vasudevan L Digital tracking, provider decision support systems, and targeted client communication via mobile devices to improve primary health care. Cochrane Database Syst. Rev. 4(4), CD012925 (2025).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"e_1_3_8_87_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.mayocp.2014.12.026","article-title":"Digital health interventions for the prevention of cardiovascular disease: a systematic review and meta-analysis","volume":"90","author":"Widmer RJ","year":"2015","unstructured":"Widmer RJ, Collins NM, Collins CS Digital health interventions for the prevention of cardiovascular disease: a systematic review and meta-analysis. Mayo Clin. Proc. 90(4), 469\u2013480 (2015).","journal-title":"Mayo Clin. Proc."},{"key":"e_1_3_8_88_2","doi-asserted-by":"crossref","first-page":"105114","DOI":"10.1016\/j.ijmedinf.2023.105114","article-title":"The effect of digital interventions on related health literacy and skills for individuals living with chronic diseases: a systematic review and meta-analysis","volume":"177","author":"Verweel L","year":"2023","unstructured":"Verweel L, Newman A, Michaelchuk W The effect of digital interventions on related health literacy and skills for individuals living with chronic diseases: a systematic review and meta-analysis. Int. J. Med. Inform. 177, 105114 (2023).","journal-title":"Int. J. Med. Inform."},{"issue":"2","key":"e_1_3_8_89_2","doi-asserted-by":"crossref","first-page":"e2356070","DOI":"10.1001\/jamanetworkopen.2023.56070","article-title":"Digital health interventions for hypertension management in US populations experiencing health disparities: a systematic review and meta-analysis","volume":"7","author":"Katz ME","year":"2024","unstructured":"Katz ME, Mszar R, Grimshaw AA Digital health interventions for hypertension management in US populations experiencing health disparities: a systematic review and meta-analysis. JAMA Netw. Open 7(2), e2356070 (2024).","journal-title":"JAMA Netw. Open"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:15:37Z","timestamp":1770286537000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.57264\/cer-2025-0162"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0162","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"e250162"}}